Ronald Davis: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(video)
(working group)
Line 3: Line 3:


==Institute of Medicine report==
==Institute of Medicine report==
Dr. Davis was one of the experts on the "Committee on the Diagnostic Criteria for [[Myalgic Encephalomyelitis]]/[[Chronic Fatigue Syndrome]]" that was convened as per US government request for the 2015 [[Institute of Medicine report]].<ref>http://www.ncbi.nlm.nih.gov/books/NBK284904/</ref> The [[Institute of Medicine]] has since changed its name to the [[National Academy of Medicine]].<ref>https://nam.edu/</ref>


Dr. Davis was one of the experts on the "Committee on the Diagnostic Criteria for [[Myalgic Encephalomyelitis]]/[[Chronic Fatigue Syndrome]]" that was convened as per US government request for the 2015 [[Institute of Medicine report]].<ref>http://www.ncbi.nlm.nih.gov/books/NBK284904/</ref> The [[Institute of Medicine]] has since changed its name to the [[National Academy of Medicine]].<ref>https://nam.edu/</ref>
==ME/CFS Common Data Element (CDE) Project==
Member of the Biomarkers Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the [[National Institute of Neurological Disorders and Stroke]] and the [[Centers for Disease Control and Prevention]].<ref>https://www.commondataelements.ninds.nih.gov/ReportViewer.aspx?%2fnindscdereports%2fRoster&rs%3aCommand=Render&rc:Parameters=false&diseaseid=MECFS&custom:disableExcel=true&custom:disableXML=true&custom:disableCSV=true</ref>


==Open Letter to ''The Lancet''==  
==Open Letter to ''The Lancet''==  
Line 15: Line 17:


In February 2017, Dr. Davis explained in a [https://www.youtube.com/watch?v=sGBXXlQO49g video] that the development of new nanofabricated technology allows rapid drug screening via measurement of electrical impedance. This technology may be able to determine which medications could be most effective in treating [[myalgic encephalomyelitis]]/[[chronic fatigue syndrome]]. Experimentation is also being carried out to test if this same nanofabricated technology could be used in developing a simple [[diagnostic biomarker|diagnostic test]] for [[myalgic encephalomyelitis]]/[[chronic fatigue syndrome]].<ref>https://www.youtube.com/watch?v=sGBXXlQO49g</ref>
In February 2017, Dr. Davis explained in a [https://www.youtube.com/watch?v=sGBXXlQO49g video] that the development of new nanofabricated technology allows rapid drug screening via measurement of electrical impedance. This technology may be able to determine which medications could be most effective in treating [[myalgic encephalomyelitis]]/[[chronic fatigue syndrome]]. Experimentation is also being carried out to test if this same nanofabricated technology could be used in developing a simple [[diagnostic biomarker|diagnostic test]] for [[myalgic encephalomyelitis]]/[[chronic fatigue syndrome]].<ref>https://www.youtube.com/watch?v=sGBXXlQO49g</ref>


==Talks and Interviews==
==Talks and Interviews==

Revision as of 17:04, June 23, 2018

RonaldDavis.jpeg

Ronald Wayne Davis, PhD., is a Professor of Biochemistry & Genetics and the Director of the Stanford Genome Technology Center at Stanford University. His son, Whitney Dafoe, is severely ill with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Professor Davis leads the End ME/CFS Project with the Open Medicine Foundation whose first project was the ME/CFS Severely Ill, Big Data Study.[1]

Institute of Medicine report[edit | edit source]

Dr. Davis was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened as per US government request for the 2015 Institute of Medicine report.[2] The Institute of Medicine has since changed its name to the National Academy of Medicine.[3]

ME/CFS Common Data Element (CDE) Project[edit | edit source]

Member of the Biomarkers Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.[4]

Open Letter to The Lancet[edit | edit source]

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. The first, written in 2015, was signed by Dr. Davis and five of his colleagues. In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.

ME/CFS Research[edit | edit source]

In March 2016, it was announced that the ME/CFS Severely Ill, Big Data Study had a significant result in the area of mitochondria. This lead to the addition of Dr. Robert Naviaux (a mitochondrial expert) to the research team.[5]

In February 2017, Dr. Davis explained in a video that the development of new nanofabricated technology allows rapid drug screening via measurement of electrical impedance. This technology may be able to determine which medications could be most effective in treating myalgic encephalomyelitis/chronic fatigue syndrome. Experimentation is also being carried out to test if this same nanofabricated technology could be used in developing a simple diagnostic test for myalgic encephalomyelitis/chronic fatigue syndrome.[6]


Talks and Interviews[edit | edit source]

2017

Mendelspod podcast
Transcript
YouTube video
Transcript

2016

Online presence[edit | edit source]

Advocacy efforts[edit | edit source]

Dr. Ron Davis and his wife, Dr. Janet Dafoe, protested with #MillionsMissing at the San Francisco satellite protest on May 25, 2016.[8] Dr. Davis gave a speech about the challenges ME patients face, and his hopes for the future of ME research.[9] To see video of Dr. Davis's interview at the San Francisco #MillionsMissing click HERE.

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]